Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Id, Randomised, Double-Blind, Placebo-Controlled, Multiple-Dose Bridging Study To Evaluate The Pharmacokinetics, Safety, Tolerability, and Immunogenicity of XKH001 in Healthy Adult Caucasian Participants

NCT07757659 is registered in ClinicalTrials.gov with Zhejiang Kanova Biopharmaceutical Co., LTD as lead sponsor.

NCT NCT07757659
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07757659 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Id, Randomised, Double-Blind, Placebo-Controlled, Multiple-Dose Bridging Study To Evaluate The Pharmacokinetics, Safety, Tolerability, and Immunogenicity of XKH001 in Healthy Adult Caucasian Participants
Lead sponsor
Zhejiang Kanova Biopharmaceutical Co., LTD
Phase
Phase 1
Overall status
Not yet recruiting
Start date
August 1, 2026
Completion date
August 1, 2027
Enrollment
2 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy adult